The fourth issue was that the amount of TR reduction was modest. Only 70% of repair patients had moderate or less TR at 30 days, versus 30% of controls. That is less complete than reported in TRILUMINATE.
The endpoint that drove the results were open to bias in this open label trial. In the win ratio, the HF hospitalization endpoint did the work: 9,280 vs 2,871 wins. Death rates were close (4,366 vs 3,166), and 74% of pairs were tied on death. Hospitalization, of course, is a clinician decision. Since everyone knows the treatment assignment, it's easy to give an increase in oral diuretics to a patient with a device while admitting a patient without one.
When we treat infections, especially serious ones in the heart and bloodstream, there are a couple of important endpoints-and one is not days without antibiotics, but recurrence of infection or death.
The bottom line is that you don't need to be an academic or infectious disease specialist to take from this trial data that the shorter course is clearly the worse strategy.
My issue is the author's choice of primary and secondary endpoints. A rule of evidence is that you choose as the primary endpoint the most important outcome. Secondary outcomes are chosen to bolster or support the primary. POET II authors got this backward; but readers of the trial can still make conclusions from the evidence-it's just different from what the authors conclude.
Given the aggressiveness of these devices and their costs (approximately $20,000 plus disposables x many ambulances), I would think we would abandon them. That is, if the treatment of patients with out of hospital cardiac arrest is to remain an evidence-based intervention.
While there were limitations of this data, including the lack of granular data on both patients and agencies, there was not any signal of benefit in the outcome of interest. Note here that the outcome of interest was not the quality of CPR, which may have been better, but survival and survival with neurologic recovery. Here, there was no signal of benefit.
Enter the polypill: what if you could take one tablet that had multiple drugs in it? This reduces the work of being a patient and it may even increase adherence to beneficial drugs.
A korrent is a belief a person has stated in their own words: one
sentence stating the claim, backed by a quote and a source, kept at
korrents.com.
Under a name here, the quoted block is what they actually said.
The korrent beneath it is the claim those words support, in
korrents' wording — tap it to see the record, its source, and who
else holds it.
Nobody here wrote their own korrents. They are compiled from public
statements, and a person can change their mind, which is recorded too.
About the English under a post
Some people here publish in a language other than English. Where they
do, this site shows a machine translation beneath the post, in
this typeface — the site's own, not theirs.
The post itself is never changed, moved or hidden: what is set in the
serif above is exactly what the person published, and it is what to
quote them on. A translation can be wrong in ways that matter,
especially about tone.
Only the post's own words are translated. A quoted post, a linked
article and a belief on korrents.com
are left in their original language.